These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19029147)

  • 1. Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.
    Wrench D; Waters R; Carlotti E; Iqbal S; Matthews J; Calaminici M; Gribben J; Lister TA; Fitzgibbon J
    Haematologica; 2009 Jan; 94(1):148-50. PubMed ID: 19029147
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome.
    Machado-Neto JA; Traina F; De Melo Campos P; Andreoli-Risso MF; Costa FF; Olalla Saad ST
    Neoplasma; 2012; 59(5):530-5. PubMed ID: 22668018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
    Cescon DW; Bradbury PA; Asomaning K; Hopkins J; Zhai R; Zhou W; Wang Z; Kulke M; Su L; Ma C; Xu W; Marshall AL; Heist RS; Wain JC; Lynch TJ; Christiani DC; Liu G
    Clin Cancer Res; 2009 May; 15(9):3103-9. PubMed ID: 19383811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
    Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
    Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
    Isakova J; Talaibekova E; Aldasheva N; Vinnikov D; Aldashev A
    BMC Cancer; 2017 Nov; 17(1):758. PubMed ID: 29132330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher-grade transformation of follicular lymphoma -- a continuous enigma.
    Lossos IS
    Leukemia; 2005 Aug; 19(8):1331-3. PubMed ID: 15902286
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
    Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
    Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
    Davies AJ; Lee AM; Taylor C; Clear AJ; Goff LK; Iqbal S; Cuthbert-Heavens D; Calaminici M; Norton AJ; Lister TA; Fitzgibbon J
    Leukemia; 2005 Aug; 19(8):1459-65. PubMed ID: 15902285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
    Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
    PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
    Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
    Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of a SNiP of the MDM2 gene to modulate the p53 pathway and the predisposition to cancer].
    Larsen CJ
    Bull Cancer; 2011 Jan; 98(1):10. PubMed ID: 21591298
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.
    McGraw KL; Cluzeau T; Sallman DA; Basiorka AA; Irvine BA; Zhang L; Epling-Burnette PK; Rollison DE; Mallo M; Sokol L; Solé F; Maciejewski J; List AF
    Oncotarget; 2015 Oct; 6(33):34437-45. PubMed ID: 26416416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers.
    Forslund A; Zeng Z; Qin LX; Rosenberg S; Ndubuisi M; Pincas H; Gerald W; Notterman DA; Barany F; Paty PB
    Mol Cancer Res; 2008 Feb; 6(2):205-11. PubMed ID: 18314481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
    Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
    Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy.
    Zavarykina TM; Tyulyandina AS; Khokhlova SV; Khabas GN; Asaturova AV; Nosova YA; Brenner PK; Kapralova MA; Atkarskaya MV; Khodyrev DS; Burdennyi AM; Loginov VI; Stenina MB; Sukhikh GT
    Bull Exp Biol Med; 2020 Aug; 169(4):486-490. PubMed ID: 32910383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Neuronal Ischemic Tolerance Is Conditioned by the Tp53 Arg72Pro Polymorphism.
    Ramos-Araque ME; Rodriguez C; Vecino R; Cortijo Garcia E; de Lera Alfonso M; Sanchez Barba M; Colàs-Campàs L; Purroy F; Arenillas JF; Almeida A; Delgado-Esteban M
    Transl Stroke Res; 2019 Apr; 10(2):204-215. PubMed ID: 29687302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.